Read our latest publications

5 November 2024

Pressures on supply of plasma-derived medicines and how to manage plasma collection within the public sector are constantly in focus at IPFA
Over the past year, we have collaborated with blood collectors, plasma fractionators and health authorities to assess these issues in depth. We have also engaged with the International Society for Blood Transfusion and in the EU funded SUPPLY project in specific areas.
We have addressed challenges faced by LMIC, and the need for strategic independence in the supply of plasma-derived medicinal products by public health systems all over the world.

Our work has generated several products, including Reports to the SUPPLY project and a number of peer-reviewed publications. Some major findings are common for all:

  • The development of healthcare includes access to plasma-derived medicinal products (PDMPs) as essential therapies for a number of medical conditions.
  • Strategic independence from the vagaries of the commercial market necessitates the generation of a supply of high-quality plasma from domestic donors.
  • A number of models exist for the use of this plasma, depending on the state of the health system, but all of them conferring control of the supply of PDMPs on the public health service.

 

We at IPFA warmly thank our collaborators for a enabling us to share the new publications with you, and look forward to any response or inquires at info@ipfa.nl.

Securing commitment and control for the supply of plasma derivatives for public health systems:
I. A short review of the global landscape
II. A survey of national pathways

Generating pathways to domestically sourced plasma-derived medicinal products
Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion.

 

This report is part of the project “101056988/SUPPLY” which has received funding from the European Union’s EU4Health Programme (2021-2027). The content of this report represents the views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HaDEA) or any other body of the European Union.
The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.